Baloise – FY gross premiums CHF 6.72bn (vs cons CHF 6.84bn) / combined ratio 94% (vs 94.5%) / net profit CHF 707.1m (vs cons CHF 670.4m) Outlook: looking for targeted acquisitions – to cancel 2.4% of outstanding shares (BB)

Schmolz&Bickenbach – FY sales EUR 2.756bn (vs EUR 2.395bn) / EBIT EUR 227m (vs EUR 186m) / net profit EUR 144.6m (vs 114m) Outlook: company sees good earnings in 2007 (BB)

SEZ – FY EBIT CHF 38.7m (vs cons CHF 37.5m) / net profit CHF 36.5m (vs cons CHF 32.5m) Outlook: anticipates the high sales level to continue, reaching at least CHF 200m in the first half of 2007 (BB)

Swisscom – submits formal offer to buy Fastweb to the Italian regulators – expect offering period to start first half of April and may be finished end of May (BB)

Roche – said no causal link can be established between certain nervous system side effects and use of Tamiflu antiviral treatment (BB)

UBS – UBS proposes Fiat’s Sergio Marchionne to Board of Directors at its AGM on April 18th (BB) Bachem – UBS upgrade from neutral to buy and increase price target from CHF 95 to CHF 110 (UBS research update)

Arbonia Forster – CS IB downgrade from outperform to neutral on valuation grounds – price target unchanged CHF 590 (CS IB research update)

Kuoni – the CEO said there is no limit to growth – we are now big enough to maintain independence despite consolidation in the industry (BB)

Lindt&Sprüngli – CEO in press: plans to double sales to CHF 5bn in coming years helped by NorthAmerica and China (HZ)